Celyad Oncology SA (CYAD) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

argenx SE

MDxHealth SA

BioSenic SA

DMS Imaging SA

Celyad Oncology SA

Why is Celyad Oncology SA ?

Unrated Stock - No Analysis Available

Real-Time Research Report

Verdict Report

No Data Found

Is Celyad Oncology SA for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Celyad Oncology SA

-31.58%

-0.92

106.97%

Belgium BEL 20

24.74%

1.55

15.93%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

3.37%

EBIT Growth (5y)

12.45%

EBIT to Interest (avg)

-21.65

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.78

Sales to Capital Employed (avg)

0.03

Tax Ratio

2.28%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-4.62

EV to EBIT

-2.02

EV to EBITDA

-2.16

EV to Capital Employed

-3.57

EV to Sales

13.61

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

Negative BV

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bullish

Bearish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bearish

Dow Theory

No Trend

Mildly Bearish

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

15What is working for the Company

OPERATING CASH FLOW(Y)

Highest at EUR -12.58 MM

RAW MATERIAL COST(Y)

Fallen by -99.84% (YoY

PRE-TAX PROFIT(Q)

Highest at EUR 4.5 MM

NET PROFIT(Q)

Highest at EUR 4.5 MM

EPS(Q)

Highest at EUR 0.11

-1What is not working for the Company

DEBTORS TURNOVER RATIO(HY)

Lowest at 0.02 times

Here's what is working for Celyad Oncology SA

Pre-Tax Profit

At EUR 4.5 MM has Grown at 252.71%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (EUR MM)

Net Profit

At EUR 4.5 MM has Grown at 258.18%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very positive

Net Profit (EUR MM)

Operating Cash Flow

Highest at EUR -12.58 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (EUR MM)

Pre-Tax Profit

Highest at EUR 4.5 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (EUR MM)

Net Profit

Highest at EUR 4.5 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is positive

Net Profit (EUR MM)

EPS

Highest at EUR 0.11

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (EUR)

Raw Material Cost

Fallen by -99.84% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Celyad Oncology SA

Debtors Turnover Ratio

Lowest at 0.02 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio